613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies

Christoph Röllig, Björn Steffen, Nael Alakel, et al.

Authors Conclusion from the Abstract: The interim analysis results show that in good responders, the difference between CR rates after single versus double induction was even smaller than the predefined 7.5% margin, suggesting a trend for non-inferiority of single induction, although statistical significance was not reached. The trial continued recruitment. These findings suggest that in good responders, it may be safe to omit a second induction cycle if a second cycle poses a high risk.

Huafeng Wang, Jianfeng Zhou, Jianyong Li, et al.

Authors Conclusion from the Abstract: The efficacy of subcutaneous injection of cytarabine was non-inferior to continuous intravenous infusion of cytarabine for the standard induction therapy in young adult de novo AML. The toxicity is equivalent between two groups. Subcutaneous injection of cytarabine offers a convenient and inexpensive alternative therapy to young adult de novo AML.

Farhad Ravandi, Asad Bashey, Wendy Stock, et al.

Authors Conclusion from the Abstract: Vibecotamab demonstrated evidence of antileukemic activity in heavily pretreated patients with relapsed/refractory AML treated at the ≥0.75 µg/kg doses cohorts, with a 14% response rate. CRS was the most common toxicity but was generally manageable with premedications. The study is ongoing with further optimization of dose and schedule. Biomarker data suggest a population of AML patients that are more likely to respond. Additional information will be provided at the time of the meeting.

Daniel A. Pollyea, Courtney D. Dinardo, Martha L. Arellano, et al.

Authors Conclusion from the Abstract: Ven+Aza compared to Aza monotherapy resulted in higher response rates, longer DoR, and mOS among treatment-naïve pts with IDH1/2 mut ineligible for intensive chemotherapy. The safety profile was acceptable. No unexpected toxicities were noted with Ven+Aza combination.

Maël Heiblig, Hélène Labussière, Marie Virginie Larcher, et al.

Authors Conclusion from the Abstract: These results confirm that post-induction NPM1 MRD1 is a reliable tool to assess disease outcome in elderly AML patients. However, the presence of DNMT3a also identify a subgroup of patients at very high risk of relapase, despite good molecular responses. As hematopoietic stem cell transplantation (HSCT) might improve OS in elderly patients, DNMT3a positive AML elderly patients should be considered for HSCT or post induction maintenance strategies, even within the favorable ELN risk group.

Muhned Alhumaid, Georgina S. Daher-Reyes, Aaron D Schimmer, et al.

Authors Conclusion from the Abstract: These findings suggest that in AML patients with DTAmut, MFC-MRD status at the time of remission assessment can be a tool for MRD assessment when NGS-based MRD assessment is limited. Further study is strongly warranted to reach a clearer conclusion with multiple cohorts.